BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1257 related articles for article (PubMed ID: 29473971)

  • 1. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 4. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.
    Wang C; Zhang Y; Zhang T; Shi L; Geng Z; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1667-1693. PubMed ID: 35702041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Present and Future of Novel Protein Degradation Technology.
    Xia L; Liu W; Song Y; Zhu H; Duan Y
    Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
    Liang Y; Nandakumar KS; Cheng K
    Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
    Pettersson M; Crews CM
    Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontiers in PROTACs.
    Hughes GR; Dudey AP; Hemmings AM; Chantry A
    Drug Discov Today; 2021 Oct; 26(10):2377-2383. PubMed ID: 33872800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments of PROTACs technology in immune-related diseases.
    Wang C; Zhang Y; Deng J; Liang B; Xing D
    Eur J Med Chem; 2023 Mar; 249():115127. PubMed ID: 36724631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTACs: New method to degrade transcription regulating proteins.
    Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
    Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
    Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
    Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
    Wang C; Zhang Y; Xing D; Zhang R
    Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.